Tocilizumab for juvenile idiopathic arthritis:a rapid health technology assessment
Objective To evaluate the efficacy,safety and economy of tocilizumab for juvenile idiopathic arthritis(JIA)and provide evidence for clinical treatment and potential entry to the National Essential Medicine List.Methods Six Chinese and English databases including PubMed,Embase,Cochrane Library,CNKI,Wanfang and SinoMed were searched by computer,as well as eight HTA related websites.Content includes literature related to tocilizumab and JIA.Two reviewers independently screened the literatures,collected the data,and conducted qualitative analysis and rapidly assessed the health technology.Results Totally 22 systematic review/Meta-analysis and 4 economic studies were included.The efficacy,safety and economy of tocilizumab for JIA were analyzed.The risk ratio was 1.48[95％confidence interval:1.03～2.13].All 22 reports in the literature showed rare adverse events.The economics study showed better cost-effect can be achieved with tocilizumab.Conclusion Tocilizumab is effective,safe and economic for JIA.
tocilizumabjuvenile idiopathic arthritisrapid health technology assessmentchild
万方数据
维普
